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Abstract
There is increasing emphasis on patient-centred research to support the development, approval and reimbursement of health 
interventions that best meet patients’ needs. However, there is currently little guidance on how meaningful patient engage-
ment may be achieved. An expert working group, representing a wide range of stakeholders and disciplines, was convened 
by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 
(ESCEO) and the World Health Organization (WHO). Through a structured, collaborative process the group generated practi-
cal guidance to facilitate optimal patient engagement in clinical development and regulatory decisions. Patient engagement 
is a relational process. The principles outlined in this report were based on lessons learned through applied experience and 
on an extensive dialogue among the expert participants. This practice guidance forms a starting point from which tailoring 
of the approach to suit different chronic diseases may be undertaken.
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Introduction
The patient perspective is now increasingly recognized as 
key in the development, conduct and evaluation of health 
interventions. The 2015 World Health Organization (WHO) 
report on healthy ageing identified that self-care plays a 
critical role in health, with increasing patient participation 
leading to better health outcomes in older adults including 
improvements in physical activity, chronic pain and self-
efficacy [1]. By involving patients at all stages of health-
care delivery and evaluation, the aim of enhancing self-care 
in patients with chronic, non-communicable disease may 
be achieved [2, 3]. Patient-centred care requires an under-
standing of a variety of patient-relevant components that 
go beyond medical diagnostic and treatment-related issues. 
They comprise psychosocial life-related challenges and a 
focus on patient engagement that acknowledges that patients 
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have an important role to play in their own healthcare. This 
includes three pillars [4]:
1. Health literacy Enabling patient to read, understand and 
act on quality health information;
2. Shared decision making and personal care planning 
Enhancing self-determination and working with clini-
cians to select appropriate treatments or management 
options [5];
3. Quality improvement Providing patient relevant feedback 
on healthcare processes and outcomes.
Patient engagement in healthcare decisions respects 
patient autonomy increases the likelihood that treatments 
would be aligned with patient (group) needs and preferences 
and ultimately leads to better outcomes for all concerned 
[6]. The complementary impact on society includes reduc-
ing healthcare and research waste through the efficient use 
of resources, as is the focus of health economics [7, 8]. This 
applies at all levels in society and thus includes individual 
clinical decisions. The promotion of patient-centeredness is 
not limited to improving healthcare, but is relevant for the 
entire life cycle of medicines.
To support the development, approval and reimbursement 
of medical interventions that best meet patients’ needs, there 
is increasing emphasis on patient-centred research through 
the engagement of patients in identifying unmet needs [9], 
the design and conduct of clinical studies [10], subsequent 
regulatory assessments [11], post-marketing vigilance and 
data collection. Patient engagement in clinical practice 
guideline development is also recommended by many organ-
izations [12–17]. Despite the many ongoing pilots, there is 
currently little practical guidance on how effective patient 
engagement may be facilitated. In this paper, we examine 
how patients’ perspectives can inform the development of 
clinical research and regulatory decisions. Our aim was 
to generate practical guidance to facilitate optimal patient 
engagement in these decisions and to raise awareness of its 
value.
Methods
An expert working group meeting was organized by the 
European Society for Clinical and Economic Aspects of 
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 
(ESCEO) and the WHO, and held in Geneva, Switzerland, 
on June 9, 2017. The working group comprised a global 
representation of clinicians, outcome researchers, social 
scientists, epidemiologists, health technology assessment 
(HTA) and regulatory experts, pharmacists and patient 
representatives. They were invited for their expertise and 
knowledge regarding patient engagement and preference 
research. Agreement on the principles outlined in this arti-
cle was based on an exchange of peer-reviewed publications 
prior to the meeting and a 1 day interactive meeting with 
short presentations and intense discussion among the meet-
ing participants.
At the meeting, results from a literature review of meth-
ods for incorporating patients’ preferences into decision-
making were presented followed by an introduction to 
the nomenclature of patient engagement and a case study 
on improving the quality of delivering integrated care by 
involving older people (I. Araujo de Carvalho, I. Aujoulat, 
M. Hiligsmann). Next, organizations including the European 
Medicines Agency (EMA) and the Outcomes Measures in 
Rheumatology (OMERACT) initiative introduced their 
principles for engagement and presented lessons learned 
through applied experiences (N. Bere, M. de Wit). After 
the presentations, a prolonged discussion among the expert 
group members took place, focused on the application of 
these principles in different contexts, and shared conclusions 
were reached.
Following the meeting, members of the writing group 
(M. de Wit, C. Cooper, N. Bere, P. Tugwell, P. G. Conaghan, 
C. Roberts, I. Aujoulat) drafted a first report on the meet-
ing, which was reviewed and commented on by all authors. 
In this resulting article, we define the concepts of patient 
involvement at different levels and discuss patient engage-
ment within the three areas: patient preference elicitation, 
outcomes research and regulatory processes. Case studies 
from the EMA and the Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis (GRAPPA) (following 
OMERACT principles) exemplify our approach.
Definitions
There are complementary approaches to capturing patients’ 
perspectives in health research and health services innova-
tion, to ensure that research and development of medical 
interventions adequately meet patients’ needs. Patients in 
different numbers may contribute to subsequent phases of a 
process, carrying out a variety of tasks and on different lev-
els. Different terminology is used, and it is first important to 
clarify these concepts [18, 19]. We distinguish the following 
patient roles in patient involvement.
Consultation involves participation of patients and/or 
their representatives as study participants; their role may be 
to trial an investigational agent and/or to provide information 
on their own individual experience. This level of involve-
ment requires predominantly a flow of information in one 
direction from patient to researcher. Protocols for participa-
tion in a clinical trial or other means of data collection such 
as surveys, interviews or focus groups are well developed 
and highly regulated through the Helsinki declaration.
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Advice is provided by an informed patient, e.g., by dis-
cussing new developments and sharing personal knowledge 
and experience, or by reviewing research grant applications 
or a scientific publication. The involvement is often limited 
to one occasion.
Collaboration may be undertaken through multiple roles, 
e.g., patient research partner (PRP), or patient expert [18]. 
A patient expert may be defined as an ‘expert’ in their own 
disease and its management, and someone who is equipped 
to look further than their own personal experience of the 
disease. Patient collaboration takes place on a collective 
level and influences the aims, design and conduct of a study 
through dialogue, two-way communication in partnership 
with other stakeholders.
Control is achieved when a patient organization takes the 
lead, determines the research gap or research questions, con-
trols the study and owns the data.
We will use the terms engaging patients and patient 
involvement as synonyms for the process of enabling people 
with a long-term condition to provide a meaningful contri-
bution to research or the improvement in healthcare services. 
Patient empowerment is a process whereby the person devel-
ops more control over decisions and actions that affect their 
own life and health [20, 21]. This involves helping a per-
son to learn to think critically and make informed decisions 
about self-care to reduce symptoms from the chronic disease 
[22]. There is increasing recognition that patient empower-
ment is a core element of quality oriented, sustainable health 
systems of the future [23]. However, because the focus of 
this article is on engaging patients in the context of health 
research and medicine development and authorisation, we 
will not elaborate on patient empowerment.
Patient engagement in patient preference 
elicitation
The assessment of patient preferences could help to improve 
disease management, facilitate shared decision-making and 
improve adherence, whilst increasing the use of patient pref-
erences in health policy making may improve the quality 
of decisions and increase efficiency [24]. For example, the 
collection of individual preferences may inform regulatory 
review processes [25]. Preference studies offer a systematic 
approach to gathering information on the distribution of 
preferences in a population and the implications on patients’ 
acceptance of specific treatments. Although the usefulness 
of stated preference studies is still not well established, such 
studies, along with other methods such as focus groups and 
expert opinions, have the potential to become an important 
tool for gathering patient views in a systematic way to esti-
mate treatment acceptability and concordance, and thus 
inform regulatory and treatment decisions [26].
Qualitative and quantitative methods could be used to 
identify what is important to patients with respect to health-
care decision-making. Stated preference methods have been 
increasingly used in HTA to elicit preference [24]. The most 
often used stated-preference methods include discrete choice 
experiment (DCE) [27, 28], best–worst scaling (BWS) 
[29], and analytical hierarchy process (AHP) [30, 31]. As 
an example, Rothery et al. used a DCE to assess patient 
preference for treatment-related benefits and risk of disease 
relapse in the management of low disease states of psoriatic 
arthritis (PsA) [32]. The study found that among patients 
in low disease states of PsA, respondents were willing to 
accept greater risk of relapse (up to 30% increased risk) for 
an improvement in the side effects of sickness and nausea 
and health status.
Patients’ preferences are nowadays increasingly sought in 
healthcare decision-making. By example, the US Food and 
Drug Administration (FDA) has developed an initiative for 
the consideration of patient preferences for multiple end-
points in development assessment of new health technolo-
gies in medical devices (FDA Medical Device Patient Prefer-
ence initiative) [33]. The FDA has also provided definitive 
guidance on the use of patient reported outcome measures 
for use in trials to support labelling claims [34], and the 
EMA has developed guidance on the use of patient reported 
outcomes in anticancer studies [35].
In Europe, there are several initiatives which aim to 
increase the use of patient preferences in policy decision-
making, which include:
• The German Institute for Quality and Efficiency in 
Healthcare (IQWiG) may include patient preference in 
cost–benefit assessment as part of the economic evalua-
tion.
• The National Institute for Health and Care Excellence 
(NICE) assessment of utility impact involves the elicita-
tion of general population preferences.
• The EMA piloted swing weighting to elicit patient pref-
erences for benefit/risk analysis for market authorization 
[25]. This was followed up with a larger study eliciting 
preferences of over 550 multiple myeloma patients on 
benefits and risks of cancer treatments to illustrate how 
such data may be used to estimate patients’ acceptance 
of new treatments [26].
• The PROTECT (Pharmacoepidemiological Research on 
Outcomes of Therapeutics by a European Consortium) 
project, conducted by the Innovative Medicines Initiative 
(IMI) and coordinated by the EMA, focuses on the ques-
tion of public/patient involvement in regulatory processes 
[36].
• IMI PREFER (Patient Preferences in Benefit-Risk 
Assessments during the Drug Life Cycle) project initi-
ated late 2016 focuses on eliciting patient perspectives 
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for use in benefit-risk assessment (BRA) and health tech-
nology assessment (HTA) [37]. PREFER will result in 
recommendations regarding the best ways to perform and 
include patient-preference in the decision-making pro-
cess of industry, regulatory authorities and HTA bodies.
These initiatives have focused on the role of patient pref-
erences through the life cycle of medicines and for regu-
latory decision making. Incorporating the preferences of 
patients in clinical decision-making (shared decision mak-
ing) is another dimension that could be the focus of future 
initiatives [38].
Patient engagement in clinical outcomes 
research
Initiatives to increase patient engagement in aspects of 
clinical research have been undertaken by a wide range 
of research communities. Engagement may involve the 
patient, relatives, informal carers or patient representatives, 
all of whom can give a relevant stakeholder perspective on 
research and healthcare innovation. The patient engagement 
process is evolving, and roles for patients may vary with 
increasing degrees of involvement, from steering group 
members, committee or working party members with vot-
ing rights, to PRPs or Delphi participants [39].
Here we explore the experience of the OMERACT Ini-
tiative. OMERACT sets out to achieve consensus about 
core outcome sets (endpoints) for clinical trials and longi-
tudinal observational studies in rheumatology, with patient 
involvement an integral part of the process [10]. OMERACT 
defines the PRP as a person with a relevant disease who 
operates as an equal member in the research team to pro-
vide the patient perspective in every phase of the study [40]. 
PRPs share decision-making power with professionals, can 
take on any role similar to all other members and have full 
voting rights at the biannual meeting [18]. Practical recom-
mendations for patient engagement in research teams were 
published in 2016 [40].
Other initiatives that have developed rules and pilots to 
include PRPs in their research activities:
• European League Against Rheumatism (EULAR) pub-
lished practical recommendations for the inclusion of 
patient representatives in scientific projects [41]. They 
are widely followed by all working groups developing 
disease management recommendations for rheumatic 
conditions.
• COMET (Core Outcome Measures in Effectiveness Tri-
als) brings together people interested in the development 
and application of agreed standardised outcome sets used 
in clinical research [42]. COMET has established a Peo-
ple and Patient Participation, Involvement and Engage-
ment (PoPPIE) Working Group that develops practical 
resources for PRPs.
• The Standardised Outcomes in Nephrology (SONG) 
initiative aims to establish a set of core outcomes and 
outcome measures across the spectrum of kidney disease 
for trials and other forms of research. The outcomes will 
be developed based on the shared priorities of patients, 
caregivers, clinicians, researchers, policy makers and rel-
evant stakeholders. This will help to ensure that research 
is reporting outcomes that are meaningful and relevant to 
patients with kidney disease, their family and their clini-
cians. Currently in development are core outcomes for 
haemodialysis (SONG-HD), transplantation (SONG-Tx), 
peritoneal dialysis (SONG-PD) children and adolescents 
(SONG-Kids), and polycystic kidney disease (SONG-
PKD) [43].
• Based on the concept of value-based healthcare, the 
International Consortium for Health Outcomes Measure-
ment (ICHOM) brings together global teams of physician 
leaders, outcomes researchers and patient advocates to 
define Standard Sets of outcomes for clinical practice that 
matter most to patients. ICHOM captures the patient per-
spective both by conducting qualitative research to col-
lect data on patient preferences as by active involvement 
of patient experts in the consensus building process. The 
final standard sets then drive adoption to enable health-
care providers globally to compare, learn and improve 
[44].
• The Patient-Centered Outcomes Research Institute 
(PCORI) has developed the PCORI Engagement Rubric, 
which provides a framework for operationalizing engage-
ment to incorporate patients and other stakeholders in all 
phases of research. The aim is to encourage active and 
sustained engagement of patients as partners in planning, 
conducting and disseminating research, to improve clini-
cal decision-making and outcomes [45].
Case study 1: GRAPPA core outcomes set in PsA
GRAPPA is a non-profit organisation focused on identifying 
and initiating research projects, advancing standardized cri-
teria for PsA registries and developing treatment guidelines. 
GRAPPA was formed in 2003 of > 600 rheumatologists, der-
matologists, radiologists, geneticists, methodologists, epide-
miologists and biopharmaceutical industry representatives 
with an interest in PsA and psoriasis research. Since 2013, 
patient research partners participate in the annual meetings 
and a variety of working groups. A best practice case study 
of patient participation in the update of the PsA core domain 
set is outlined here [46, 47].
The OMERACT-GRAPPA PsA working group met to 
review the existing PsA core set [48] based on the patient 
Aging Clinical and Experimental Research 
1 3
perspective as well as new research findings and further 
develop PsA responder indices. The group discussed the 
need to revise the PsA core set, and opportunities to add, 
move, or merge existing domains to better integrate the 
patient perspective and to remove redundancy; and how to 
incorporate the core set in a composite index [49].
OMERACT recommendations for patient involvement 
were followed and included (Fig. 1):
1. Active partnership of five PRPs in the working group 
and one PRP in the Steering Group.
2. International focus group study representing five conti-
nents and including seven countries.
3. Delphi study.
4. Consensus meeting.
New domains were identified through systematic lit-
erature review, international focus groups exploring the 
opinions and experiences of people with PsA and two inter-
national surveys with patients and physicians to prioritise 
domains. Consensus was achieved through an international 
face-to-face expert meeting with equal representation of 
patients and physicians to agree on the most important 
domains, and voting at the OMERACT 2016 conference. 
PRPs were involved at all phases of the process. As a result, 
the updated PsA core domain set incorporates patients’ and 
physicians’ priorities and includes the domains of: mus-
culoskeletal disease activity, skin disease activity, pain, 
patient global, physical function, health-related quality of 
life, fatigue and systemic inflammation [47].
Lessons learned
Challenges identified were to ensure broad representative-
ness of patients’ perspectives in demography, geography, 
disease severity and in numbers, which entails a signifi-
cant level of communication and efforts to enable equal 
collaboration. Preserving the patient perspective throughout 
the research process is of great importance and following 
from an unanticipated workload for PRPs and researchers 
it may be difficult to keep PRPs and researchers motivated 
to collaborate.
Participation requires multiple forms of engagement and 
should always be tailor-made, there is no common methodol-
ogy or application that fits every research context. In addi-
tion, participation requires a willingness for mutual learning, 
and the role of the principal investigator is key in providing 
adequate support to patients. Fruitful participation always 
requires additional resources to be allocated to the process, 
with extra effort in time, money and energy. A structural 
approach guarantees sustainability of participation.
Patient engagement in regulatory processes
Since establishment of the EMA in 1995, interaction with 
patients has developed progressively with the creation of a 
Framework for interaction with patient and consumer groups 
in 2005, a Patients and Consumers Working Party (PCWP) 
in 2006, including representatives from 20 organisations and 
a dedicated ‘public engagement’ department in 2014.
The EMA has increasingly incorporated the patients’ 
voice within its regulatory activities by way of pilot projects 
testing the various engagement methodologies, in collabora-
tion with its network of patient organisations [50, 51]. There 
are now processes to include patients at all stages along the 
regulatory lifecycle (See Case Study 2).
Case study 2: EMA methodology on patient 
engagement, a progressive journey
Patient engagement occurs at all steps along the medi-
cine regulatory lifecycle (Fig. 2). As the EMA progressed 
with involving patients in its activities, it became apparent 
that there were different levels of patient’s representation, 
Fig. 1  Patient involvement in 
all steps of the update to the 
core outcome set for psoriatic 
arthritis
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depending on the nature of the activity. The different catego-
ries are: representing the patient community; representing 
their own organisation, and patient as individual experts.
In the pre-submission phase of development, examples 
of where patients can contribute to EMA discussions on the 
design of clinical trials include:
• Selection of end-points.
• Defining target population, inclusion/exclusion criteria.
• Study duration, treatment administration, formulation 
and dosage.
• Clinical relevance versus statistical significance.
• Identification of risk potential.
• Significant benefit (added-value) over existing therapies.
• Ethical aspects, informed consent.
Lessons learned
It also became apparent that for optimal and mutually ben-
eficial engagement to occur, the following elements are vital:
• Define the role of the patient for each specific activity 
and ensure that all involved parties are informed. This 
facilitates participation and also manages expectations 
from all angles.
• Identify the most suitable patients/groups to involve in 
each situation, taking into account representation and 
confidentiality aspects.
• Establish a range of engagement methodologies and 
assess for each case which method is most suitable for 
the situation (e.g., face-to-face, in writing, surveys, 
committee meetings, preference elicitation).
• Provide individualised support and training, tailored to 
the individual and the activity, e.g., training sessions, 
videos, info-sheets, webpages, one-to-one support. To 
aid training, the European Patients’ Academy on Ther-
apeutic Innovation (EUPATI) has developed patient 
education resources in key areas of non-clinical and 
clinical development, clinical trials, regulatory affairs 
and health technology assessment [52, 53].
• Provide feedback to all involved, especially so that the 
patient sees that their input is valuable.
• Continuous monitoring and reporting on interactions, 
and refining procedures according to feedback received.
Challenges identified were in finding suitable patients 
(e.g., language barrier, availability) while ensuring repre-
sentativeness and in knowing how to also gather validated 
information from larger groups. Potential conflicts of inter-
est need to be handled sensitively. Compensation is also 
an area requiring attention. Demonstrating the value and/
or impact of patient involvement in a quantitative manner 
Fig. 2  Patient involvement can occur at all steps along the medicine development and regulatory lifecycle
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while avoiding subjectivity is a challenge; however, quali-
tative methods can be of value provided that there is suf-
ficient reflexivity and transparency. The trend in public 
health is now to use mixed methods designs.
Conclusions: principles for engaging 
with patients
Engaging with patients helps to bridge the gap between 
health research, policy and patient-centred practice, 
increases transparency and patients’ adherence to treatments, 
reduces waste and leads to more meaningful regulatory out-
comes. Patient engagement should be initiated in a stepwise 
approach through which all parties can learn together and 
identify the format that works best for all involved. At all 
stages of engagement, provide support, define roles, manage 
expectations and give feedback, to ensure that engagement 
is mutually beneficial. In this way, ultimately everyone can 
benefit from knowledge sharing.
Patient engagement is a relational process, and the nine 
principles outlined here (see Table 1) [54], form a start-
ing point from which tailoring of the approach to suit 
different chronic diseases and other healthcare context 
needs may be undertaken. Overarching principles include 
the recognition that the perspective of patients is pivotal 
in outcomes research and the decision-making process of 
medicine authorisation that earlier involvement of patients 
is always better and that involvement at all stages is neces-
sary. Patients should be offered the possibility to consult 
each other on experience-based views; furthermore, patients 
sometimes need to cancel their presence due to health issues. 
To ensure proper representation, inviting at least two PRPs is 
recommended [55]. Finally, acknowledgement of input and 
feedback to patients is essential, and integrated knowledge 
translation is desirable [56].
In this article, we acknowledge that there are different 
levels of patient engagement, all equally valuable and com-
plementary, and that the degree of patient participation and 
level of power or authority should not be mandatory but 
may be tailor-made to suit the individual research purpose. 
Patient engagement is an evolving concept, and the research 
agenda for future refinement of the process will include the 
development of new methodologies to assess the impact 
of patient engagement and novel ways to enhance the sig-
nificance of existing methods for engagement, in order to 
emphasize the role of the patient voice in health research, 
treatment guidelines and regulatory processes. The impact 
of patient engagement, in terms of added value, but also 
cost and potential downsides is currently poorly understood. 
Reasons for this include a lack of consensus on a validated 
methodology or tool to measure impact, and a lack of con-
sensus on the important outcomes of patient engagement; 
people and stakeholder groups have different expectations 
and objectives regarding patient engagement, and thus 
require different methodologies and outcomes for evaluation.
Another challenge is that we, as an expert group, all agree 
that principal investigators and stakeholders should invest 
in support, information, education and feedback to patient 
experts (see Panel); however, there is a growing awareness 
that it does not make sense to train patients in the medi-
cine development cycle, without simultaneously preparing 
researchers for their role and task of engaging patients in 
that process. Thus, there is a need to explore both the ben-
efits and downsides of educating patient experts as well as 
exploring the needs of researchers for guidance, coaching 
and training [57].
Table 1  WHO-ESCEO Principles for engaging patients in health research, treatment guidelines and regulatory processes. Table reprinted from 
de Wit et al. [54] with permission from Elsevier
9 principles for best practice
1. Patient perspective The perspective of patients is pivotal in health research, treatment guidelines, and the authorization of medicines
2. Engagement Capturing patients’ perspectives requires multiple forms of engagement that are complementary; the strategy should be 
tailored to suit different chronic diseases and contexts
3. Transparency Transparency for all stakeholders about the role of patients in the process facilitates participation and manages expecta-
tions from all perspectives
4. Representation Broad representativeness of patients’ perspectives in terms of demography, geography, disease severity and sample size 
must be ensured
5. Multiple inputs Involvement of at least two patient experts throughout the research, assessment and deliberation processes ensures that 
the patient perspective is preserved and increases the validity of the outcomes
6. Support Providing adequate information, support and feedback to patient representatives is key to effective engagement
7. Expertise Teaching researchers the knowledge and skills required to support public engagement should always be considered
8. Resources Productive participation always requires resources to be allocated to the process, with extra effort in time, money and 
energy
9. Monitor Continuous monitoring and measuring of interactions will be vital for refining procedures according to feedback
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